drugset / Trial / NCT03188783

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants

NCT03188783

Phase 1 Completed 32 enrolled Hoffmann-La Roche
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of single and multiple oral doses of GDC-0853 in healthy Japanese and Caucasian subjects.

Timeline

Start
2017-01-24
Primary completion
2017-08-09
Completion
2017-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenebrutinib Small molecule Oral

Indications

No indication recorded.